Clinical Trial: Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study

Brief Summary: Given that 5-HT3 receptors are indirect inhibitors of cortico-mesolimbic DA release, the 5-HT3 receptor antagonist ondansetron augmentation might potentially have efficacy in the treatment of resistant Obsessive Comulsive Disorder (OCD) patients on combined SRIs and antipsychotics.

Detailed Summary: METHOD: Fourteen patients with a DSM-IV diagnosis of treatment resistant OCD, under stable treatment with SSRI's and neuroleptic augmentation will enter an 12-week single blind trial of ondansetron initiated at a dose of 0.25 mg twice daily for 6 weeks, that will be titrated to 0.5 mg twice daily for 6 weeks.
Sponsor: Institute of Neuroscience, Florence, Italy

Current Primary Outcome: Yale-Brown Obsessive Compulsive Scale (Y-BOCS) [ Time Frame: 6th 12th week ]

Original Primary Outcome: Same as current

Current Secondary Outcome: clinical global impression (CGI) [ Time Frame: 6th e 12th ]

Original Secondary Outcome: Same as current

Information By: Institute of Neuroscience, Florence, Italy

Dates:
Date Received: November 20, 2008
Date Started: March 2008
Date Completion:
Last Updated: February 23, 2011
Last Verified: February 2011